SCHEMBL5448559

SCHEMBL5448559

O=C(O)c1cc(CSc2ccccc2C(F)(F)F)on1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 1/20 0.45
TTR P02766 1/20 0.45
HTT P42858 1/20 0.41
KMO O15229 1/20 0.40
ALDH1A1 P00352 4/20 0.39
RAB9A P51151 6/20 0.38
NPC1 O15118 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
LMNA P02545 1/20 0.38
FDPS P14324 1/20 0.38
KMT2A Q03164 2/20 0.37
ALOX5 P09917 1/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
XBP1 P17861 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458916 0.86 HDAC6 (0.46) HTTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL17289074 0.83 HTT (0.43) TTRHTTKMOALDH1A1RAB9A
SCHEMBL5456139 0.81 RXRA (0.38) KMOALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL5447826 0.77 SMN1; SMN2 (0.43) HTTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL5445311 0.76 PPARD (0.53) RAB9ANPC1SMN1; SMN2LMNAKMT2A
SCHEMBL5449783 0.71 DAO (0.48) ALDH1A1RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL15932023 0.71 ALDH1A1 (0.46) ALDH1A1RAB9ANPC1SMN1; SMN2FDPS
SCHEMBL5453461 0.70 EPHX1 (0.47) HTTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL6818423 0.70 SCD5 (0.58) KMOALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL29775908 0.70 SCD5 (0.58) KMOALDH1A1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US claimed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP claimed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO claimed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP disclosed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors PDF, MRPL21, PEPD RBP4 955/4885TTR 3566/4885HTT 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.